View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsHongda Xingye 과거 순이익 실적과거 기준 점검 0/6Hongda Xingye 의 수입은 연평균 -25.1%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 5.6%의 비율로 감소했습니다. 매출은 연평균 5.5%의 비율로 감소해 왔습니다.핵심 정보-25.13%순이익 성장률-25.40%주당순이익(EPS) 성장률Chemicals 산업 성장률12.10%매출 성장률-5.45%자기자본이익률-8.57%순이익률-24.93%다음 순이익 업데이트29 Apr 2024최근 과거 실적 업데이트공고 • Dec 30Hongda Xingye Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024Hongda Xingye Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 3Q 2022)Third quarter 2023 results: CN¥0.11 loss per share (down from CN¥0.003 profit in 3Q 2022). Revenue: CN¥270.7m (down 78% from 3Q 2022). Net loss: CN¥337.2m (down CN¥345.4m from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.057 profit in 2Q 2022)Second quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.057 profit in 2Q 2022). Revenue: CN¥1.11b (down 33% from 2Q 2022). Net loss: CN¥478.4m (down 371% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.033 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.033 in 1Q 2022). Revenue: CN¥834.2m (down 8.3% from 1Q 2022). Net income: CN¥1.96m (down 98% from 1Q 2022). Profit margin: 0.2% (down from 11% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.21 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.25b (down 42% from 3Q 2021). Net income: CN¥8.24m (down 99% from 3Q 2021). Profit margin: 0.7% (down from 25% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year.Reported Earnings • Sep 03Second quarter 2022 earnings released: EPS: CN¥0.057 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.057 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥1.67b (down 11% from 2Q 2021). Net income: CN¥176.4m (down 66% from 2Q 2021). Profit margin: 11% (down from 28% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공고 • Dec 30Hongda Xingye Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024Hongda Xingye Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 3Q 2022)Third quarter 2023 results: CN¥0.11 loss per share (down from CN¥0.003 profit in 3Q 2022). Revenue: CN¥270.7m (down 78% from 3Q 2022). Net loss: CN¥337.2m (down CN¥345.4m from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.공고 • Oct 19Hongda Xingye Co., Ltd.(XSEC:002002) dropped from S&P Global BMI IndexHongda Xingye Co., Ltd.(XSEC:002002) dropped from S&P Global BMI IndexNew Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.0% average weekly change).Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.057 profit in 2Q 2022)Second quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.057 profit in 2Q 2022). Revenue: CN¥1.11b (down 33% from 2Q 2022). Net loss: CN¥478.4m (down 371% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.Board Change • Aug 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • May 06Hongda Xingye Co., Ltd., Annual General Meeting, May 22, 2023Hongda Xingye Co., Ltd., Annual General Meeting, May 22, 2023, at 15:00 China Standard Time. Agenda: To consider 2022 annual report and its summary; to consider 2022 work report of the board of directors; to consider 2022 work report of the supervisory committee; to consider 2022 annual accounts; to consider 2022 profit distribution plan; to consider Confirmation of 2022 continuing connected transactions of the Company and its subsidiaries and 2023 estimated continuing connected transactions; to consider 2022 special report on the deposit and use of raised funds; and to consider other matters.Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.033 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.033 in 1Q 2022). Revenue: CN¥834.2m (down 8.3% from 1Q 2022). Net income: CN¥1.96m (down 98% from 1Q 2022). Profit margin: 0.2% (down from 11% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.21 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.25b (down 42% from 3Q 2021). Net income: CN¥8.24m (down 99% from 3Q 2021). Profit margin: 0.7% (down from 25% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year.Reported Earnings • Sep 03Second quarter 2022 earnings released: EPS: CN¥0.057 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.057 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥1.67b (down 11% from 2Q 2021). Net income: CN¥176.4m (down 66% from 2Q 2021). Profit margin: 11% (down from 28% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥4.31, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 2.6% over the past three years.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.099 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.033 (down from CN¥0.099 in 1Q 2021). Revenue: CN¥909.4m (down 45% from 1Q 2021). Net income: CN¥102.5m (down 62% from 1Q 2021). Profit margin: 11% (down from 16% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 5 independent directors (6 non-independent directors). Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 20Full year 2021 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in FY 2020)Full year 2021 results: EPS: CN¥0.33 (up from CN¥0.31 in FY 2020). Revenue: CN¥6.52b (up 21% from FY 2020). Net income: CN¥851.8m (up 4.7% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.098 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.14b (up 63% from 3Q 2020). Net income: CN¥538.4m (up 114% from 3Q 2020). Profit margin: 25% (up from 19% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥5.49, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 70% over the past three years.Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥6.45, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 122% over the past three years.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.055 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.89b (up 60% from 2Q 2020). Net income: CN¥521.9m (up 270% from 2Q 2020). Profit margin: 28% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥4.94, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 37% over the past three years.Reported Earnings • May 01First quarter 2021 earnings released: EPS CN¥0.099 (vs CN¥0.074 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.64b (up 14% from 1Q 2020). Net income: CN¥269.4m (up 41% from 1Q 2020). Profit margin: 16% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥4.13, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 35x in the Chemicals industry in China. Total loss to shareholders of 32% over the past three years.Reported Earnings • Apr 04Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.24 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥5.39b (up 1.8% from FY 2019). Net income: CN¥813.8m (up 29% from FY 2019). Profit margin: 15% (up from 12% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 18% per year.Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥3.72, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 37x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 43%.Is New 90 Day High Low • Dec 30New 90-day low: CN¥2.95The company is down 22% from its price of CN¥3.80 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥3.18, the stock is trading at a trailing P/E ratio of 11.3x, down from the previous P/E ratio of 13.3x. This compares to an average P/E of 36x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 52%.Valuation Update With 7 Day Price Move • Dec 16Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥3.09, the stock is trading at a trailing P/E ratio of 10.9x, down from the previous P/E ratio of 13.5x. This compares to an average P/E of 37x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 53%.Is New 90 Day High Low • Dec 15New 90-day low: CN¥3.42The company is down 19% from its price of CN¥4.24 on 17 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: CN¥4.28The company is up 9.0% from its price of CN¥3.92 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: CN¥3.60The company is down 8.0% from its price of CN¥3.92 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥726.8m, up 67% from the prior year. Total revenue was CN¥5.17b over the last 12 months, down 10% from the prior year.매출 및 비용 세부 내역Hongda Xingye가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XSEC:002002 매출, 비용 및 순이익 (CNY Millions)날짜매출순이익일반관리비연구개발비30 Sep 233,212-80177211330 Jun 234,189-45557212531 Mar 234,74719949112331 Dec 224,82230047511530 Sep 224,690-19117817630 Jun 225,57833922818231 Mar 225,79168523317001 Jan 226,52385224317930 Sep 217,1291,56031316730 Jun 216,3031,27325915831 Mar 215,59389220215931 Dec 205,39481423215630 Sep 205,17172716511930 Jun 205,07268720811231 Mar 205,33663133711831 Dec 195,30063033310430 Sep 195,77943359213430 Jun 195,95446663612431 Mar 196,03754965711131 Dec 186,04561165711130 Sep 186,0428137221730 Jun 186,4049206712431 Mar 186,4589536921831 Dec 176,5411,0056871830 Sep 177,3841,153636430 Jun 176,9941,047602031 Mar 176,3721,014527031 Dec 166,158818508030 Sep 164,870743433030 Jun 164,570631355031 Mar 164,585591357031 Dec 154,087559347030 Sep 153,949428273030 Jun 153,825427276031 Mar 153,536361217031 Dec 143,320347196030 Sep 142,875360178030 Jun 142,505311171031 Mar 142,481330145031 Dec 132,417296142030 Sep 132,34930389030 Jun 132,31026582031 Mar 132,044188800양질의 수익: 002002 은(는) 현재 수익성이 없습니다.이익 마진 증가: 002002는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 002002은 수익성이 없으며 지난 5년 동안 손실이 연평균 25.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 002002의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 002002은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(3.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 002002는 현재 수익성이 없으므로 자본 수익률이 음수(-8.57%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/03/20 10:26종가2024/01/18 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hongda Xingye Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Xiaofeng QiuEverbright Securities Co. Ltd.Xi LiuHuatai Research
공고 • Dec 30Hongda Xingye Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024Hongda Xingye Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 3Q 2022)Third quarter 2023 results: CN¥0.11 loss per share (down from CN¥0.003 profit in 3Q 2022). Revenue: CN¥270.7m (down 78% from 3Q 2022). Net loss: CN¥337.2m (down CN¥345.4m from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.057 profit in 2Q 2022)Second quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.057 profit in 2Q 2022). Revenue: CN¥1.11b (down 33% from 2Q 2022). Net loss: CN¥478.4m (down 371% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.033 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.033 in 1Q 2022). Revenue: CN¥834.2m (down 8.3% from 1Q 2022). Net income: CN¥1.96m (down 98% from 1Q 2022). Profit margin: 0.2% (down from 11% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.21 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.25b (down 42% from 3Q 2021). Net income: CN¥8.24m (down 99% from 3Q 2021). Profit margin: 0.7% (down from 25% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year.
Reported Earnings • Sep 03Second quarter 2022 earnings released: EPS: CN¥0.057 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.057 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥1.67b (down 11% from 2Q 2021). Net income: CN¥176.4m (down 66% from 2Q 2021). Profit margin: 11% (down from 28% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Dec 30Hongda Xingye Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024Hongda Xingye Co., Ltd. announced that they will report fiscal year 2023 results on Apr 29, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 3Q 2022)Third quarter 2023 results: CN¥0.11 loss per share (down from CN¥0.003 profit in 3Q 2022). Revenue: CN¥270.7m (down 78% from 3Q 2022). Net loss: CN¥337.2m (down CN¥345.4m from profit in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
공고 • Oct 19Hongda Xingye Co., Ltd.(XSEC:002002) dropped from S&P Global BMI IndexHongda Xingye Co., Ltd.(XSEC:002002) dropped from S&P Global BMI Index
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 17% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.0% average weekly change).
Reported Earnings • Aug 31Second quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.057 profit in 2Q 2022)Second quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.057 profit in 2Q 2022). Revenue: CN¥1.11b (down 33% from 2Q 2022). Net loss: CN¥478.4m (down 371% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
Board Change • Aug 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • May 06Hongda Xingye Co., Ltd., Annual General Meeting, May 22, 2023Hongda Xingye Co., Ltd., Annual General Meeting, May 22, 2023, at 15:00 China Standard Time. Agenda: To consider 2022 annual report and its summary; to consider 2022 work report of the board of directors; to consider 2022 work report of the supervisory committee; to consider 2022 annual accounts; to consider 2022 profit distribution plan; to consider Confirmation of 2022 continuing connected transactions of the Company and its subsidiaries and 2023 estimated continuing connected transactions; to consider 2022 special report on the deposit and use of raised funds; and to consider other matters.
Reported Earnings • Apr 30First quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.033 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.033 in 1Q 2022). Revenue: CN¥834.2m (down 8.3% from 1Q 2022). Net income: CN¥1.96m (down 98% from 1Q 2022). Profit margin: 0.2% (down from 11% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.21 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.003 (down from CN¥0.21 in 3Q 2021). Revenue: CN¥1.25b (down 42% from 3Q 2021). Net income: CN¥8.24m (down 99% from 3Q 2021). Profit margin: 0.7% (down from 25% in 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 7% per year.
Reported Earnings • Sep 03Second quarter 2022 earnings released: EPS: CN¥0.057 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.057 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥1.67b (down 11% from 2Q 2021). Net income: CN¥176.4m (down 66% from 2Q 2021). Profit margin: 11% (down from 28% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥4.31, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 2.6% over the past three years.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.099 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.033 (down from CN¥0.099 in 1Q 2021). Revenue: CN¥909.4m (down 45% from 1Q 2021). Net income: CN¥102.5m (down 62% from 1Q 2021). Profit margin: 11% (down from 16% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 5 independent directors (6 non-independent directors). Independent Director Ruihao Liao was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 20Full year 2021 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in FY 2020)Full year 2021 results: EPS: CN¥0.33 (up from CN¥0.31 in FY 2020). Revenue: CN¥6.52b (up 21% from FY 2020). Net income: CN¥851.8m (up 4.7% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 26Third quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.098 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.14b (up 63% from 3Q 2020). Net income: CN¥538.4m (up 114% from 3Q 2020). Profit margin: 25% (up from 19% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥5.49, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 70% over the past three years.
Valuation Update With 7 Day Price Move • Sep 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥6.45, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 122% over the past three years.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.055 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.89b (up 60% from 2Q 2020). Net income: CN¥521.9m (up 270% from 2Q 2020). Profit margin: 28% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥4.94, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 37% over the past three years.
Reported Earnings • May 01First quarter 2021 earnings released: EPS CN¥0.099 (vs CN¥0.074 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.64b (up 14% from 1Q 2020). Net income: CN¥269.4m (up 41% from 1Q 2020). Profit margin: 16% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Apr 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to CN¥4.13, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 35x in the Chemicals industry in China. Total loss to shareholders of 32% over the past three years.
Reported Earnings • Apr 04Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.24 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥5.39b (up 1.8% from FY 2019). Net income: CN¥813.8m (up 29% from FY 2019). Profit margin: 15% (up from 12% in FY 2019). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 18% per year.
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥3.72, the stock is trading at a trailing P/E ratio of 13.2x, up from the previous P/E ratio of 11.2x. This compares to an average P/E of 37x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 43%.
Is New 90 Day High Low • Dec 30New 90-day low: CN¥2.95The company is down 22% from its price of CN¥3.80 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥3.18, the stock is trading at a trailing P/E ratio of 11.3x, down from the previous P/E ratio of 13.3x. This compares to an average P/E of 36x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 52%.
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥3.09, the stock is trading at a trailing P/E ratio of 10.9x, down from the previous P/E ratio of 13.5x. This compares to an average P/E of 37x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 53%.
Is New 90 Day High Low • Dec 15New 90-day low: CN¥3.42The company is down 19% from its price of CN¥4.24 on 17 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: CN¥4.28The company is up 9.0% from its price of CN¥3.92 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: CN¥3.60The company is down 8.0% from its price of CN¥3.92 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period.
Reported Earnings • Oct 29Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥726.8m, up 67% from the prior year. Total revenue was CN¥5.17b over the last 12 months, down 10% from the prior year.